PSTI.TA - Pluristem Therapeutics Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
475.90
+13.90 (+3.01%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close462.00
Open463.00
Bid475.80 x 32000
Ask475.90 x 849800
Day's Range457.10 - 477.30
52 Week Range390.00 - 739.00
Volume456,169
Avg. Volume354,459
Market Cap509.208M
Beta0.31
PE Ratio (TTM)N/A
EPS (TTM)-0.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire10 days ago

    Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic collaboration with Thermo Fisher Scientific to advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. Together, the companies hope to transform cell therapy manufacturing into a large-scale, high capacity industry that will enable the production of millions of therapeutic doses of regenerative medicines.

  • GlobeNewswire24 days ago

    Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today reported positive data from studies conducted in collaboration with Fukushima Medical University evaluating PLX-R18 cells as a treatment for radiation damage to the gastrointestinal (GI) tract and bone marrow. Data from these studies showed that PLX-R18 cells significantly increase survival rates, preserve GI stem cells activity that enhance the recovery of the GI system and prevents severe damage to the intestinal lining, suggesting PLX-R18 potential as a multi-organ therapy for acute radiation syndrome (ARS). Under a Memorandum of Understanding (MOU) with Pluristem, Fukushima University, Fukushima Global Medical Science Center, has been developing targeted animal models of ARS and has been testing these models in studies to evaluate the efficacy of PLX-R18 in treating radiation damage to the GI tract and bone marrow of mice.

  • GlobeNewswirelast month

    U.S. Department of Defense to Study Pluristem’s PLX-R18 for the Treatment of Mustard Gas Injuries

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today it has entered into an additional collaboration agreement with the U.S. Department of Defense (DOD) and its United States Army Medical Research Institute of Chemical Defense (USAMRICD) to study the Company’s PLX-R18 cell therapy product in the treatment of long term lung injuries following exposure to mustard gas. The DOD is also studying the effectiveness of PLX-R18 as a novel medical countermeasure for Acute Radiation Syndrome (ARS) prior to exposure to high levels of radiation, designed to support the needs of the U.S. Armed Forces.

  • GlobeNewswirelast month

    Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results

    HAIFA, Israel, June 14, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, is delighted to announce that it has been invited by the Tel Aviv Stock Exchange ...

  • Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?
    Simply Wall St.last month

    Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?

    In this article, I will take a look at Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent earnings update (31 March 2018) and compare these latest figures against its performance over theRead More...

  • Reuterslast month

    Israel's Pluristem sees positive results from leg pain study

    Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent ...

  • GlobeNewswirelast month

    Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC). PLX-PAD treatment reduced Incidence of revascularization and improved patients’ mobility. Study results also validate the design of Pluristem’s ongoing Pivotal Phase III study in CLI, a more severe stage of peripheral arterial disease (PAD) and confirm Pluristem’s proprietary Bio-Therapeutic approach.

  • Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock
    Zackslast month

    Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock

    Investors in Pluristem Therapeutics (PSTI) need to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswirelast month

    Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today announced that the top-line results of the company’s multinational Phase II clinical trial of PLX-PAD cells in the treatment of Intermittent Claudication (IC) will be released on June 12, 2018. Pluristem's Phase II IC trial is evaluating the safety and efficacy of PLX-PAD cells as compared to placebo in 172 patients with IC, Rutherford category 2-3.

  • Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?
    Simply Wall St.2 months ago

    Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?

    Pluristem Therapeutics Inc’s (NASDAQ:PSTI): Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The US$156.33M market-cap posted a loss in its most recentRead More...

  • Associated Press2 months ago

    Pluristem: Fiscal 3Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 1 cent per share. The company's shares closed at $1.33. A year ago, they were trading at $1.32. _____ This story was generated by Automated Insights ...

  • GlobeNewswire2 months ago

    Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, today reported financial results and corporate developments for its third quarter of fiscal 2018 ended March 31, 2018. “The past few months brought several significant milestones which we believe are key to our continued development”, stated Pluristem Chairman and Co-CEO Zami Aberman. “The U.S. Food and Drug Administration (FDA) has cleared our Investigational New Drug application (IND) for the use of PLX-R18 in treating victims who may have been acutely exposed to high dose radiation (ARS) due to nuclear attack or accident.

  • Benzinga3 months ago

    FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next?

    Pluristem Therapeutics Inc. (NASDAQ: PSTI ), which develops placenta-based cell therapy products, announced Monday that the FDA cleared an investigational new drug application for PLX-R18 cell therapy ...

  • GlobeNewswire3 months ago

    U.S. FDA Clears Pluristem’s IND to Treat Victims Exposed to Acute Radiation

    HAIFA, Israel, April 30, 2018-- Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration has cleared the Company’ ...

  • Reuters3 months ago

    FDA clears Pluristem radiation treatment for emergency use

    Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event. Pluristem said it will start preparations to keep an emergency stock of PLX-R18 on hand for use in such events. Full approval of the drug will depend on the results of a Phase III clinical trial.

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! MannKind Corporation (NASDAQ: MNKD ) stock was trading ...

  • GlobeNewswire3 months ago

    U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA) has cleared Pluristem’s Investigational Drug Application (IND) for a Phase III study of its PLX-PAD cell therapy in the treatment of muscle injury following surgical repair (arthroplasty) of the hip joint due to fracture. Pluristem is in discussions with several EU countries to approve this study in Europe as well and expects to begin patient enrollment in both regions during 2018. The Phase III study follows positive results from a Phase I/II trial which demonstrated significant muscle regeneration when using PLX-PAD cells in total hip arthroplasty patients.

  • GlobeNewswire3 months ago

    Pluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study

    The 5- year joint project was granted $2.5 million from the U.S. National Institutes of Health Data from these studies will support BLA filing for marketing approval of PLX-R18 in the treatment of ARS ...

  • What You Must Know About Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Major Investors
    Simply Wall St.5 months ago

    What You Must Know About Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Major Investors

    I am going to take a deep dive into Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • Reuters6 months ago

    N.Korea threats spur U.S. search for new radiation therapies

    The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome. The hostility between the two nations reached a new height last November after Pyongyang fired an intercontinental ballistic missile capable of reaching the U.S. mainland. The DoD's budget allocated $3.9 million of its total funding to develop such medical countermeasures in 2018, an increase of $600,000 from a year ago.